Neurodegenerative signature

Key concepts

Assessed comparisons:

  • MBM-1 and MBM-2: melanoma metastatic cells in the brain compared to other melanoma metastatic locations
  • AD-CT: cortex brain region from Alzheimer’s disease patients compared to cortex brain region from controls.
  • AD-HP: hippocampus brain region from Alzheimer’s disease patients compared to hippocampus brain region from controls.
  • PD-SN: substantia nigra brain region from Parkinson’s disease patients compared to substantia nigra brain region from controls.
  • PD-ST: striatum brain region from Parkinson’s disease patients compared to striatum brain region from controls.
  • MS: brain samples from multiple sclerosis patients compared to brain samples from controls.

Evaluation of the transcription pattern change in significant genes of each comparison:

  • Upregulated genes (UP, logFC > 0): genes more expressed in the first condition of the comparison (i.e. melanoma metastatic cells in the brain for MBM-1 and MBM-2, or case samples for the neurodegenerative meta-analyses).

  • Downregulated genes (DOWN, logFC > 0): genes more expressed in the second condition of the comparison (i.e. other melanoma metastatic locations for MBM-1 and MBM-2, or control samples for the neurodegenerative meta-analyses).

Neurodegenerative signature of melanoma brain-specific metastasis

Gene dysregulation profile by study/meta-analysis of the neurodegenerative signature:

Gene profile melanoma brain-specific metastasis

Gene dysregulation profile by study/meta-analysis of the melanoma brain-specific metastasis genes (MBM-1 and MBM-2).

Back to top